Abstract
The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow charts. The major changes in this new edition are as follows—(1) the format has been changed from reviews to clinical questions (CQ), and the guidelines for optimal clinical practice in Japan are now shown as 41 CQs and answers; (2) the ‘flow charts’ have been improved and placed near the beginning of the guidelines; (3) the ‘basic points’, including tumor staging, histological classification, surgical procedures, chemotherapy, and palliative care, are described before the chapter; (4) the FIGO surgical staging of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was revised in 2014 and the guideline has been revised accordingly to take the updated version of this classification into account; (5) the procedures for examination and management of hereditary breast and ovarian cancer are described; (6) information on molecular targeting therapy has been added; (7) guidelines for the treatment of recurrent cancer based on tumor markers alone are described, as well as guidelines for providing hormone replacement therapy after treatment.
Similar content being viewed by others
References
Cancer Mortality in Japan (2012) Center for Cancer Control and Information Services. National Cancer Center, Japan. http://ganjoho.jp/professional/statistics/statistics.html. Accessed 15 Sept 2014
Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192
Gynecologic Cancer Committee (2012) Gynecologic cancer committee report in 2011. Acta Obstet Gynaecol Jpn 66:1024–1038
Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29:970–977
Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29:1047–1054
Fukui T, Yoshida M, Yamaguchi N (2007) Minds Guidance of practice guidelines 2007. Igakushoin, Tokyo
Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21:1–12
Japanese Society of Clinical Oncology clinical practice guidelines 2013 for G-CSF. http://www.jsco-cpg.jp/item/30/index.html
Acknowledgments
Creation of this guideline was supported by the Japan Society of Gynecologic Oncology with contributions from “Encouragement of wider use of practice guidelines for cancer and their effects, as well as investigation of guideline projects” (chief investigator: Koichi Hirata), Research for Promotion of Cancer Control Programmes (2014), and a Health and Labour Sciences Research Grant. The funding sources did not influence the contents of this guideline.
Conflict of interest
The conflict-of-interest committee of the Japan Society of Gynecologic Oncology checked conflicts of interest for the people involved in creating and evaluating this guideline and their associates (i.e., marital partner, first-degree relatives, or people sharing income/assets), according to the “Guidelines for conflict of interest issues in clinical studies on cancer” (http://www.jsgo.or.jp/topics/index01.html) published by the Japan Society of Gynecologic Oncology. Although there were conflicts of interest for some contributors through research/lecture activities supported by companies, the recommendations in this guideline are based on scientific evidence and have not been influenced by the interests of a specific organization and are not biased in recommending or products or techniques.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article originally appeared in Japanese as Ransougan Chiryo guideline 2015 nen-ban, published by Kanehara & Co., Ltd, Tokyo, Japan.
Guidelines for treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer 2015 (4th edition)
Guidelines for treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer 2015 (4th edition)
Guideline development committee
Mitsuya Ishikawa, Fumiaki Isohashi, Yoshio Itani, Kimihiko Ito, Masahiro Iwasaki, Yasuhiko Ebina, Yoshihiro Ohishi, Hideyuki Ohtake, Tatsuru Oohara, Hiroaki Kajiyama, Noriyuki Katsumata, Kazuyoshi Kato, Shingo Kato, Masanori Kanemura, Kei Kawana, Takako Kiyokawa, Keisuke Kurose, Shinichi Komiyama, Kimiko Sato, Morio Sawada, Tadahiro Shoji, Masashi Takano, Hiroshi Tanabe, Hiroshi Tsubamoto, Fumitoshi Terauchi, Yasuhisa Terao, Kimihiro Nagai, Yoshifumi Nakao, Satoru Nagase, Kentaro Nakayama, Koji Nishino, Hiroyuki Nomura, Kazuhiko Hayashi, Eiji Hirata, Kiyoshi Fujiwara, Hiroyuki Fujiwara, Masayuki Futagami, Yusuke Matsuura, Noriomi Matsumura, Koji Matsumoto, Yoshiki Mikami, Yo Miyahara, Toshinari Muramatsu, Hidekazu Yamada, Kiyoshi Yoshino, Yoshimitsu Ryo, and Hidemichi Watari (in order of the Japanese syllabary).
Guideline review committee
Satomi Aihara, Daisuke Aoki, Yoichi Aoki, Seiji Isonishi, Hiroaki Itamochi, Kazuhiko Ino, Osamu Iwanari, Kimio Ushijima, Masahide Ohmichi, Kazunori Ochiai, Takashi Onda, Hidenori Kato, Junzo Kigawa, Satoru Kyo, Hiroyuki Kuramoto, Hiroaki Kobayashi, Tsuyoshi Saito, Noriaki Sakuragi, Toyomi Satoh, Kiyosumi Shibata, Toru Sugiyama, Mitsuaki Suzuki, Kazuhiro Takehara, Shinichi Tate, Tsutomu Tabata, Katsuhiro Teramoto, Takafumi Toita, Takafumi Nakamura, Kaei Nasu, Toru Hachisuga, Kenichi Harano, Fumiki Hirahara, Ichio Fukasawa, Keiichi Fujiwara, Satoru Makinoda, Koji Miyazaki, Masanori Yasuda, Yoshihito Yokoyama, Hiroyuki Yoshikawa, and Kosuke Yoshinaga (in order of the Japanese syllabary).
About this article
Cite this article
Komiyama, S., Katabuchi, H., Mikami, M. et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer . Int J Clin Oncol 21, 435–446 (2016). https://doi.org/10.1007/s10147-016-0985-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-016-0985-x